Change search
ReferencesLink to record
Permanent link

Direct link
Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Clinical chemistry.
Show others and affiliations
2013 (English)In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, ISSN 2167-8421, Vol. 14, no 3, 199-204 p.Article in journal (Refereed) Published
Abstract [en]

The mutated SOD1 protein appears to have a gene dose-dependent effect on the severity and progression of ALS. Lowering of SOD1 protein levels might reduce severity and progression of the disease. The antimalarial drug pyrimethamine (PYR) was identified to cause a dose-dependent reduction in SOD1 protein levels in human cells in vitro. To determine if there was a similar effect in humans, we performed a phase I pilot study in 16 ALS patients with SOD1 mutations, 18 weeks in duration. Blood samples were obtained during all visits. The actin normalized leukocyte SOD1 levels were analyzed using Western blot. SOD1 content in the cerebrospinal fluid (CSF) was determined by ELISA and the SOD1 enzymic activity by spectrophotometric analysis using KO2. Clinical assessment of disease severity was assessed using Appel ALS scale and ALSFRS-R. The leukocyte SOD1 levels showed a significant reduction (p < 0.0001) by the third study visit and this reduction was sustained throughout the remainder of the study. CSF also showed a decrease in SOD1 protein content and enzymic activity in the two patients so tested. Thus, PYR use may be associated with a reduction in SOD1 in ALS patients. The significance is uncertain and further detailed study is required.

Place, publisher, year, edition, pages
London: Informa Healthcare, 2013. Vol. 14, no 3, 199-204 p.
Keyword [en]
Clinical trials, pyrimethamine, SOD1, therapy, ALS
National Category
Clinical Medicine
URN: urn:nbn:se:umu:diva-70135DOI: 10.3109/17482968.2012.724074ISI: 000316952900007OAI: diva2:620634
Available from: 2013-05-09 Created: 2013-05-06 Last updated: 2014-03-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Andersen, Peter M.Marklund, Stefan
By organisation
Clinical NeuroscienceClinical chemistry
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 63 hits
ReferencesLink to record
Permanent link

Direct link